ArticleBritish journal of clinical pharmacology2018

Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.

Nidal Al-Huniti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.